Analytical Control of Darunavir Tablet Dosage Forms. Part I.


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Purposeful development of special methods to be included into pharmacopoeial monographs on the quality of darunavir (DRV) preparations is shown to allow the use of expensive imported standard samples (SSs) for drug analysis to be avoided. Part I of the present work describes these methods and their validation. UV spectrophotometry is proposed in the “Authenticity” section for detecting DRV by the coincidence of extrema in the spectrum of an aqueous MeOH extract (pH 9) with well-known peaks in the spectrum of deprotonated DRV at 230 nm (minimum) and 267 nm (maximum). This section also requires GC analysis for solvated EtOH, the presence of which indicates that DRV ethanolate was used as the active pharmaceutical ingredient (API) and the absence of which, that non-solvated amorphous DRV was used. The significant increase in the accuracy of the quantitative determination and the sharp reduction in its duration allow the use of SSs to be avoided. For this reason, the “Dissolution” section proposes determining the DRV concentration in the dissolution medium (pH 3) by spectrophotometry using a method that requires experimental determination of the specific absorption coefficient \( \left({A}_{1\mathrm{cm}}^{1\%}\right) \) of DRV solutions in this medium at the maximum (267 nm). The established value \( \left({A}_{1\mathrm{cm}}^{1\%}\right. \) = (393.4 ± 2) cm–1 was a physicochemical constant with a relative standard deviation RSD < 1% at confidence level α = 0.05.

About the authors

M. S. Goizman

Drug Technology Co.

Author for correspondence.
Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400

A. A. Korlyukov

A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences

Email: goizmanmi@gmail.com
Russian Federation, 28 Vavilova St., Moscow, 119991

K. Yu. Suponitskii

A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences

Email: goizmanmi@gmail.com
Russian Federation, 28 Vavilova St., Moscow, 119991

N. L. Shimanovskii

N. I. Pirogov National Research Medical University

Email: goizmanmi@gmail.com
Russian Federation, 1 Ostrovityanova St., Moscow, 117997

T. E. Popova

Drug Technology Co.

Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400

A. O. Popova

Drug Technology Co.

Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400

O. N. Glotova

Drug Technology Co.

Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400

O. A. Zotova

Drug Technology Co.

Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400

G. B. Tikhomirova

Drug Technology Co.

Email: goizmanmi@gmail.com
Russian Federation, 2a Rabochaya St., Khimki, Moscow Oblast, 141400


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies